Met, the receptor for hepatocyte growth factor (HGF), is activated in human cancer by both ligand-dependent and -independent mechanisms. We engineered a soluble Met receptor (decoy Met) that interferes with both HGF binding to Met and Met homodimerization. By lentiviral vector technology, we achieved local or systemic delivery of decoy Met in mice. We provide evidence that in vivo expression of decoy Met (1) inhibits tumor cell proliferation and survival in a variety of human xenografts, (2) impairs tumor angiogenesis by preventing host vessel arborization, (3) suppresses or prevents the formation of spontaneous metastases, and (4) synergizes with radiotherapy in inducing tumor regression, without (5) affecting housekeeping physiological functions in the adult animal.
Introduction
. It is, however, clear that HGF/ Hepatocyte growth factor (HGF, also known as scatter factor) Met signaling is exploited by tumors to grow, survive, and exis a pleiotropic cytokine of mesenchymal origin that controls pand, mimicking developing organs or healing wounds (Birchcell proliferation, survival, motility, and differentiation in a variety meier et al., 2003; Comoglio and Trusolino, 2002; Vande Woude of tissues, including epithelial, endothelial, neuronal, and hemoet al., 1997) . poietic cells (Rubin et al., 1993; Zarnegar and Michalopoulos, While the Met receptor is expressed by most tissues of 1995; Tamagnone and Comoglio, 1997) . The coordinated orepithelial, hemopoietic, and neuronal origin, HGF is secreted chestration of these biological processes by HGF results in a by mesenchymal cells, but it accumulates ubiquitously in tissues specific genetic program known as "invasive growth" (reviewed due to its high affinity for extracellular matrix (Kobayashi et al., by Trusolino and Comoglio, 2002) . This complex program has 1994; Lyon et al., 1994) . Met overexpression is a common event evolved primarily to master vital morphogenetic processes durin human cancer (reviewed by Trusolino and Comoglio, 2002) , and may determine ligand-independent receptor activation ing embryo development and organ formation (Woolf et al., 1995; Takayama et al., 1996; Andermarcher et al., 1996) . Experi- (Wang et al., 2001) or increased sensitivity to environmental HGF (Pennacchietti et al., 2003) . mental deletion of the hgf gene-or of the gene encoding its high affinity receptor, the tyrosine kinase Met-results in placenVarious approaches have been explored to inhibit HGF or Met in experimental systems, including neutralization of HGF tal and hepatic abnormalities leading to in utero embryo death (Schmidt et al., 1995; Uehara et al., 1995; Bladt et al., 1995) .
by monoclonal antibodies (Cao et al., 2001) , ribozyme-mediated downregulation of HGF/Met expression (Jiang et al., 2001 (Jiang et al., , 2003 ; In the adult organism, the physiologic role of the HGF pathway is less well understood, although several lines of evidence Abounader et al., 2002; Herynk et al., 2003; Kim et al., 2003) , impairment of receptor dimerization by dominant-negative Met suggest that it may be involved in wound healing, tissue regeneration, hemopoiesis, and tissue homeostasis in general (Miya- (Firon et al., 2000; Furge et al., 2001) , inhibition of Met tyrosine kinase activity by small molecule inhibitors (Sattler et al., 2003;  full-size Met (not shown). Thus, decoy Met interacts with high affinity with both HGF and full-size Met. Christensen et al., 2003; , and ligand displacement by a competitive inhibitor of HGF (reviewed by Matsumoto Decoy Met inhibits Met activation mediated by HGF and Nakamura, 2003) .
or by ligand-independent mechanisms In the present study, we employed an alternative approach To test whether the engineered antagonists could inhibit ligandbased on (1) a soluble Met receptor (Michieli et al., 1999) and induced Met activation, we stimulated lentiviral vector-trans-(2) an improved lentiviral vector technology (Follenzi et al., 2000) .
duced cells with recombinant HGF, and then determined the The data presented here not only point to Met as an ideal target extent of Met tyrosine phosphorylation. In MDA-MB-435 cells, for cancer therapy, but also suggest that the extracellular portion cells transduced with NK4 HGF or decoy Met lentivirus showed of the Met receptor is a promising therapeutic agent by itself.
markedly reduced sensitivity to HGF stimulation compared to cells transduced with control lentivirus ( Figure 1E , MDA panel).
Results
Similar results were obtained with A549 cells and HUVECs, thus suggesting that both NK4 HGF and decoy Met prevent HGFEngineering of decoy Met induced Met activation in a variety of cellular models. However, To generate a soluble HGF receptor, we engineered a recombiMet is often activated in cancer by HGF-independent mechanant protein corresponding to the entire extracellular domain nisms (reviewed by Trusolino and Comoglio, 2002) . We therefore of Met, truncated before the transmembrane domain ( Figure  tested whether NK4 HGF or decoy Met could inhibit Met activa-1A). As a control, we also engineered a truncated form of HGF, tion induced by (1) overexpression or (2) oncogenic point mutaknown as NK4 HGF, which has been shown to compete with tion in different cell systems. HGF in Met binding (Matsumoto and Nakamura, 2003) . A MycIn COS cells, transient overexpression of exogenous Met epitope tag and a poly-histidine tag were added at the C termiresults in spontaneous dimerization and autoactivation due to nus of both molecules. The cDNAs for the engineered molecules very high protein levels. In this model, coexpression of decoy were subcloned into the pRRLsin.PPT.CMV.Wpre lentiviral vecMet-but not NK4 HGF-significantly reduced wild-type Met tor (Follenzi et al., 2000; Supplemental Figure S1 at http://www. phosphorylation ( Figure 1E , COS panel). In GTL16 gastric carcicancercell.org/cgi/content/full/6/1/61/DC1). Into the same vecnoma cells, Met is constitutively activated due to natural receptor, we also subcloned the cDNA for human HGF. Recombinant tor overexpression (Giordano et al., 1989) . In this system too, viral particles from recombinant vectors were produced in large expression of decoy Met dramatically reduced constitutive Met scale and used to transduce a panel of human tumor cell lines tyrosine phosphorylation, while NK4 HGF was not effective (Fig-(MDA-MB-435 and MDA-MB-435-␤4, human mammary carci- ure 1E, GTL16 panel). noma; A549, human lung carcinoma) and primary human umbiliIn hereditary and sporadic papillary carcinomas of the kidcal vein endothelial cells (HUVECs). The different recombinant ney, in sporadic hepatocellular carcinomas, and in head and factors reached comparable concentrations in the conditioned neck primary tumors and metastases, Met has been found to medium of transduced cells, approximately 30-60 nM in 72 hr be activated by point mutation (Schmidt et al., 1997; Park et (Supplemental Figure S2). al., 1999; Di Renzo et al., 2000) . To test whether NK4 HGF or decoy Met could interfere with point mutation-induced Met Decoy Met binds at high affinity to both HGF activation, we transduced TOV-112D human ovarian carcinoma and full-size Met cells (which lack Met expression; see below) with a lentiviral Starting from the conditioned medium of lentiviral vector-transvector encoding wild-type or mutated Met, or an empty vector duced tumor cells, NK4 HGF and decoy Met were purified to as control. Cells overexpressing mutant Met (M1250T) displayed homogeneity by affinity chromatography ( Figure 1B) , and their constitutive tyrosine phosphorylation ( Figure 1E , TOV panel). ability to bind Met or HGF, respectively, was analyzed by ELISA These cells were further transduced with empty, NK4 HGF, or ( Figure 1C ). Purified Fc-Met chimera was used as a control for decoy Met vector, and the extent of Met tyrosine phosphoryla-HGF binding (Mark et al., 1992) . NK4 HGF bound Met with tion was determined by immunoblotting. Once again, decoy Met approximately one log less affinity compared to HGF (HGF, K D ϭ could efficiently prevent point mutation-induced Met activation, 0.035 nM; NK4 HGF, K D ϭ 0.326 nM). In contrast, human HGF while NK4 HGF was not effective ( Figure 1E , TOV panel). Therebound decoy Met with a K D of 0.049 nM, a value which correfore, consistent with the biochemical data presented above, sponds approximately to the in vivo affinity of HGF for bona decoy Met is a soluble HGF antagonist capable of interfering fide Met (Matsumoto et al., 1998) .
with both HGF-induced and ligand-independent Met activation. Since the extracellular portion of Met is conceivably involved in receptor homodimerization, we also tested the ability of decoy Decoy Met inhibits the pleiotropic effects of HGF in vitro Met to interact with full-size Met in (1) coimmunoprecipitation
In a first experimental approach, we tested the ability of HGF experiments and (2) ELISA binding assays. In lentiviral vectorantagonists to inhibit HGF-dependent biological activity on tutransduced MDA-MB-435 cells, decoy Met (but not NK4 HGF) mor cells in a variety of in vitro assays. We subjected lentiviral coimmunoprecipitated with endogenous Met, and vice versa vector-transduced cells to (1) a proliferation assay, (2) a survival (Supplemental Figure S3) . In ELISA binding assays, purified assay, (3) a Matrigel invasion assay, (4) a branching morphogendecoy Met bound Fc-Met at high affinity ( Figure 1D ), following esis assay, and (5) a "scratch" assay, either in the absence or a biphasic curve (first site, K D ϭ 0.058 nM; second site, K D ϭ presence of recombinant HGF. This analysis revealed that both 2.840 nM). Consistent with this, we observed that two distinct NK4 HGF and decoy Met-at the concentrations reached by isolated subdomains of decoy Met, the SEMA domain and the lentiviral vector-mediated expression-effectively inhibited HGF-induced DNA synthesis (Figure 2A ), protection against IPT region, conserve the ability of coimmunoprecipitating with apoptosis ( Figure 2B ), Matrigel invasion ( Figure 2C ), branching lial cell migration and morphogenesis. Lentiviral vector-transmorphogenesis ( Figure 2D ), and scratch repair ( Figure 2E ), thus duced HUVECs were analyzed for their ability (1) to migrate demonstrating that the engineered antagonists can functionally through a fibronectin layer ( Figure 3A ) and (2) to form capillaryneutralize the effects of HGF on living cells. However, in Matrigel like branched structures in a collagen gel ( Figure 3B ), in the invasion assays using GTL16 gastric carcinoma cells, in which, presence of no factor, recombinant vascular endothelial growth as described above, Met is constitutively activated, only decoy factor (VEGF), recombinant HGF, or both VEGF and HGF. This Met inhibited cell migration in the absence of HGF, thus conanalysis revealed that VEGF and HGF cooperate in inducing firming that decoy Met-but not NK4 HGF-is capable of endothelial cell motility and particularly in promoting capillary blocking receptor activation in a dominant-negative fashion (Fig- branching (see Supplemental Figure S4 at http://www.cancercell. ure 2F).
org/cgi/content/full/6/1/61/DC1 for representative images). In both assays, decoy Met inhibited invasion mediated by HGF Decoy Met impairs HGF-induced endothelial cell but not by VEGF, indicating that its activity is specific for the migration and branching HGF/Met pathway. In contrast, as previously reported (Kuba et Since HGF is a potent angiogenic factor (Bussolino et al., 1992) , we analyzed the effect of NK4 HGF and decoy Met on endotheal., 2000), NK4 HGF inhibited equally well HGF-or VEGF-medi- ated HUVEC migration and branching. In this regard, it should reduced tumor weight, although to a lesser extent (1.3-fold, p ϭ 0.0453). Autopsy revealed that 40% of the animals in the control be noted that NK4 HGF has been found to inhibit angiogenesis independently of Met (Matsumoto and Nakamura, 2003) , group developed pulmonary metastases, while all mice of the decoy Met group and 80% of the NK4 HGF group were metastaand to share remarkable structural homology with angiostatin (O'Reilly et al., 1994) . sis-free. Symmetrically, mice injected with cells transduced with HGF lentiviral vector had a much higher tumor weight (1.9-fold, p ϭ 0.0023) and developed more metastases (30.8-fold, p ϭ Decoy Met inhibits tumor growth and metastasis in mice 0.0031). Similar results were obtained with A549 lung carcinoma cells ( Figure 4B ), and with MDA-MB-435-␤4 mammary carciWe next tested the biological effects of Met activation (by HGF) or inhibition (by NK4 HGF or decoy Met) in ex vivo tumorigenesis noma cells ( Figure 4C ), a more metastogenic variant of MDA-MB-435 (Trusolino et al., 2001 ). assays in mice. CD-1 nu Ϫ/Ϫ mice were injected subcutaneously with different tumor cell lines transduced in vitro with the various Interestingly, histological analysis of lungs revealed remarkable biological differences between micrometastases found in lentiviral vectors, and injected animals were monitored for tumor development. After 50 days, experimental tumors were exthe empty vector, NK4 HGF, and HGF groups (Supplemental Figure S5 ). In the control group, metastatic lesions were mostly tracted for analysis, and lungs were contrasted with India ink to highlight metastases. Following metastasis scoring, lungs small, parenchimatic, and sometimes infiltrated by lymphoid cells. In the NK4 HGF animals, micrometastases were poor in were processed for histological analysis.
In experiments using MDA-MB-435 mammary carcinoma infiltrated cells, but appeared well delimited and highly apoptotic. In contrast, metastases in the HGF group appeared much cells ( Figure 4A ), decoy Met dramatically reduced tumor weight compared to the control (5-fold, p Ͻ 0.0001). Also, NK4 HGF larger, mostly embolic, and free of infiltrate. Furthermore, HGF end, we subcutaneously injected MDA-MB-435-␤4 human mammary carcinoma cells into CD-1 nu Ϫ/Ϫ mice, and then monitored animals for tumor appearance. After two weeks, all mice bearing tumors of approximately 100 mm 3 were selected and randomly divided into four groups (n ϭ 6). High-titer lentiviral vector preparations were injected intratumorally, and tumor volume was measured every third day. After 18 days, mice were subjected to autopsy.
While tumors injected with empty vector enlarged more than 6-fold during the course of the experiment, injection of NK4 HGF or decoy Met almost completely arrested the growth of the neoplastic mass (NK4 HGF, p ϭ 0.0001; decoy Met, p Ͻ 0.0001; Figure 5A ). Symmetrically, HGF accelerated tumor growth by 1.6 times compared to the control (p ϭ 0.0032). Similar results emerge from analysis of tumor weight ( Figure 5B ). Immunofluorescence analysis of frozen tumor sections revealed widespread high expression of all the exogenous transgenes (Supplemental Figure S6) . To determine the presence of metastatic lesions, we analyzed serial lung sections stained with hematoxylin and eosin. We found micrometastases in all experimental groups except decoy Met ( Figure 5C ).
We also determined the proliferative index (Ki67; Figure 5D ) and apoptotic index (TUNEL; Figure 5E ) of cells within the tumors. Remarkably, decoy Met reduced tumor cell proliferation by almost 2-fold (p ϭ 0.0001) and increased apoptosis approximately 3.7 times (p Ͻ 0.0001). NK4 HGF also decreased tumor cell mitotic index (2.1-fold, p Ͻ 0.0001) and augmented apoptotic cell death (2.3-fold, p Ͻ 0.0001). HGF achieved the opposite effect on both proliferation (1.2-fold higher, p ϭ 0.0015) and apoptosis (3-fold lower, p Ͻ 0.0001). To determine vessel distribution within the transduced neoplasinvade a fibronectin layer in the presence of no factor, VEGF, HGF, or both HGF and VEGF. E, empty vector; N, NK4 HGF; D, decoy Met; CTRL, control; tic lesions described above, we stained tumor sections with
antibodies against the CD31 endothelial marker, and analyzed B: Branching morphogenesis assay. Preformed HUVEC spheroids were stimuthem by fluorescence microscopy. Three distinct parameters lated as in A and global tubule elongation was quantified by summing the were determined ( Figure 5F ): vessel density, total vessel area, length of all tubules in each colony analyzed.
and mean lumen area. Strikingly, this analysis revealed that HGF C: Branched colony complexity from the experiment described in B is expressed by the number of branch points per colony (see Supplemental increased vessel density by 1.7 times (p ϭ 0.0134), but at the same order (p ϭ 0.0046), thus not significantly changing total vessel area. In other words, HGF caused tumor vessels to be higher in number, but smaller in diameter, thus resulting in greater arborization. Conversely, decoy Met decreased vessel also promoted the formation of several "exploded" metastatic density by approximately 11 times (p ϭ 0.0178), but reduced emboli invading the lung parenchima.
total vessel area only 3.2-fold (p ϭ 0.0224), thus resulting in We wondered whether the absence of metastatic lesions in dramatically higher lumen caliber (approximately 3.5-fold, p ϭ the decoy Met group was merely due to reduced tumor size. 0.0192; see Figure 5G for representative images). Interestingly, We therefore reperformed the same analysis using MDA-MBand consistent with a different mechanism of angiogenesis inhi-435-␤4 cells on a panel of randomized animals that were all bition, NK4 HGF reduced both vessel density (1.4-fold, p ϭ bearing large tumors of the same volume (approximately 4,000 0.0017) and mean lumen area (1.4-fold, p ϭ 0.0016), thus remm 3 ) at the time of sacrifice, regardless of the time required by sulting in fewer and smaller vessels within the tumor. the tumor to reach such volume ( Figure 4D ). In this analysis as well, no metastasis at all could be found in the decoy Met Concomitant action on tumor and endothelial cells group, suggesting that decoy Met prevents tumor cell spreading by decoy Met results in optimal inhibition directly and independently of its parallel effect on tumor growth.
of tumor growth To determine whether the sole inhibition of vessel arborization Decoy Met blocks the growth and dissemination by decoy Met could have biological consequences on tumor of established tumors growth, we performed ex vivo tumorigenesis assays using the We next analyzed whether NK4 HGF or decoy Met could interfere with growth and invasion of an established tumor. To this TOV-112D human ovarian carcinoma cell line, which lacks Met expression as determined by both Western blot and RT-PCR NK4 HGF groups seemed to have recovered from their initial reserve, and grew at a high rate. By the end of the experiment, analysis ( Figure 6A ). We transduced TOV-112D cells with the full panel of lentiviral vectors, and then injected them subcutaneno statistically significant difference in tumor volume or weight could be measured between the decoy Met or NK4 HGF group ously into nude mice. Tumor growth was monitored as described above for 20 days, and then tumors were extracted for and the empty vector group. In contrast, HGF dramatically increased both tumor volume (5.3 times, p ϭ 0.0422) and weight analysis.
We first determined whether mouse vessels within the tumor (4.9 times, p ϭ 0.0378). Western blot analysis on tumor lysates ruled out the possibility that cancer cells had lost decoy Met were expressing the Met receptor. Confocal immunofluorescence analysis revealed complete signal overlapping between or NK4 HGF expression during the course of the experiment (Supplemental Figure S7B ). CD31 and mouse Met staining ( Figure 6B ). By RT-PCR analysis, we also determined that cancer cells in all tumors had not This phenomenon can be explained if we hypothesize that inhibition of angiogenesis by decoy Met or NK4 HGF applies a acquired met expression during the course of the experiment (Supplemental Figure S7A) . selective pressure on tumor cells. During an early "crisis" phase, cancer cells that have a reduced vascular demand (Rak et al., Next, we determined vessel distribution as performed for MDA-MB-435-␤4 tumors using anti-CD31 antibodies ( Figure  2002 ) are selected for, and subsequently take over the remaining tumor cell population. In contrast, HGF provides an advantage 6C). We observed that: (1) decoy Met decreased vessel density (5-fold, p Ͻ 0.0001), increased mean lumen area (2.1-fold, p ϭ to tumor cells, because it promotes angiogenesis. All in all, we can conclude that: (1) HGF sustains the growth and expansion 0.0033), and reduced total vessel area (2.4-fold, p ϭ 0.0002); (2) NK4 HGF decreased vessel density (2-fold, p ϭ 0.0003), of a tumor, even when tumor cells do not express the HGF receptor, because it promotes host vessel arborization; and mean lumen area (1.3-fold, p ϭ 0.0311), and total vessel area (2.7-fold, p Ͻ 0.0001); and (3) HGF increased vessel density (2) the sole impairment of angiogenesis by decoy Met or NK4 HGF-without a concomitant action on tumor cells-is insuffi-(1.7-fold, p ϭ 0.0006) and decreased mean lumen area (1.5-fold, p ϭ 0.0065), but did not significantly augment total vessel cient to determine a persistent inhibition of tumor growth, at least in the biologic system analyzed. area (1.1-fold, p ϭ 0.0769).
This remarkable impairment of vessel morphology by decoy Met resulted in a net 20% decrease in tumor incidence and in Systemic inhibition of HGF/Met prevents tumor growth and metastasis without substantially affecting a significant delay of tumor formation (Ͼ2.4-fold, p Ͻ 0.0029; Figure 6D ). Similarly, inhibition of vessel formation by NK4 HGF housekeeping physiological functions In our next approach, we compared the effects of systemic also decreased tumor incidence by 20%, and significantly delayed tumor formation (Ͼ2.2-fold, p Ͻ 0.0259). Consistent with HGF/Met inhibition on tumor versus normal tissues. Systemic administration of lentiviral vectors is a powerful approach to these observations, promotion of vessel arborization by HGF significantly accelerated tumor formation (2-fold, p ϭ 0.0352).
obtain sustained plasmatic levels of a secreted factor (Follenzi et al., 2002) . To this end, we injected i.v. a panel of CD-1 nu Ϫ/Ϫ However, once they appeared, all tumors of the decoy Met and mice with highly concentrated lentiviral vector preparations, and tions. We measured various clinical and biological parameters, including ability to repair a cutaneous wound, complete heobtained three distinct sets of animals expressing stable (Supplemental Figure S8 at http://www.cancercell.org/cgi/content/ mochrome and white blood cell formula, hemoglobin concentration, coagulation properties, liver and kidney function enzymes, full/6/1/61/DC1) picomolar plasma concentrations of HGF (40-100 pM), NK4 HGF (24-41 pM), or decoy Met (11-50 pM), and other markers (Table 1 and Supplemental Table S1 ). This analysis revealed that most physiological parameters were left plus one set of control animals (empty vector). Considering that endogenous HGF is found in normal mice at about 5-6 pM (Xue substantially unaffected, with a few remarkable exceptions in the NK4 HGF group. In fact, NK4 HGF increased both red (1. 2-et al., 2002) , the observed factor concentrations are certainly significant from a biological viewpoint.
fold, p Ͻ 0.0001) and white (1.1-fold, p ϭ 0.0279) blood cell numbers, while it decreased platelet concentration (1.2-fold, Between three and five weeks after injection, mice were subjected to a series of tests aimed at determining whether p ϭ 0.0278). Microscopy analysis revealed that this increment in white blood cells was contributed mainly by granulocytes sustained expression of exogenous HGF or HGF antagonists was perturbing their major housekeeping physiological func-(not shown). NK4 HGF also increased hemoglobin concentration (1.1-fold, p ϭ 0.0004; Table 1 ). Since these changes were not grew at a lower rate. However, tumor incidence was not reobserved in the decoy Met group, nor was a symmetric effect duced, suggesting that the plasmatic concentrations of NK4 elicited by HGF, hemochrome alterations induced by NK4 HGF HGF reached in these mice-in contrast with those obtained are conceivably a result of Met-independent mechanisms. No locally by direct tumor injection-may be too low to achieve a other parameter analyzed was significantly changed compared significant tumor inhibition. to the control, either in the NK4 group or in the other two.
Autopsy (see Table 1 ) was performed 46 days after tumor Approximately five weeks after lentiviral vector injection, cell injection. While all mice developed visible pulmonary lesions transduced mice were injected subcutaneously with MDA-MBin the control, NK4 HGF, and HGF groups, no metastasis could 435-␤4 cells, and tumor formation was monitored as already be detected in the decoy Met mice except for one animal. NK4 described. In striking contrast with the results obtained by ex-HGF did not reduce metastasis incidence, but only metastasis amining housekeeping physiological functions, analysis of tunumber. Metastases in the HGF group were not only higher in mor formation (Table 1 and Supplemental Figure S9A ) revealed number, but also larger and more invasive compared to the that mice expressing picomolar concentrations of decoy Met empty vector group (see Supplemental Figure S9B for represenwere less permissive to xenograft implantation, as they distative images). Histological analysis of liver and kidney sections played longer latency and reduced penetrance. Also, tumor did not reveal any obvious sign of pathology (not shown). In growth was substantially inhibited, as measured by volume incontrast, consistent with a role of HGF in hemopoiesis (Galimi crease over time. Conversely, consistent with the previous et al., 1994), bone marrow cell apoptotic index was found to in vivo data, mice expressing exogenous HGF displayed accelbe increased by NK4 HGF and decoy Met, and decreased by erated tumor formation and a higher neoplastic growth rate. In the NK4 group, tumor latency was slightly increased, and tumors HGF (Table 1) . CD-1 nu Ϫ/Ϫ mice were injected i.v. with equal amounts of the indicated lentiviral vector and then assayed for the presence of the appropriate factor in plasma (FPC, factor plasma concentration; see also Supplemental Figure S8 at http://www.cancercell.org/cgi/content/full/6/1/61/DC1). For each experimental group, 5 mice expressing sustained picomolar levels of factor were selected, and then injected subcutaneously with tumor cells. The formation of experimental tumors and of spontaneous metastases was analyzed as described in text. The same mice were subjected to a series of tests aimed at determining several biological and clinical parameters (WH, wound healing; a.i., apoptotic index; RBC, red blood cells; WBC, white blood cells; PLT, platelets; HGB, hemoglobin). Additional clinical parameters are analyzed in Supplemental Table S1 . Statistical significance (p value) was calculated by a two-tail homoscedastic Student's t test. Significant values (p Ͻ 0.05) are shown in italic. As revealed by power calculation, this analysis detects variations corresponding to 2-fold the standard deviation (SD) with a power of 80%. N/A, not applicable.
Decoy Met synergizes with radiotherapy in inducing
duced with empty vector partially regressed shortly after irradiatumor regression tion, but eventually relapsed and started to grow again within HGF/Met signaling has been implicated in chemo-and radiorea week ( Figure 7B ). Tumors transduced with HGF displayed sistance of tumors (Fan et al., 1998) . We therefore tested little if any radiosensitivity. In contrast, tumors transduced with whether decoy Met could sensitize tumor cells to radiotherapy.
decoy Met or NK4 HGF constantly regressed following irradiaWe irradiated lentiviral vector-transduced MDA-MB-435-␤4 tion and did not relapse. At the end of the experiment (day 24 cells in vitro, and determined their survival in the presence or after virus injection), tumors transduced with empty vector or absence of recombinant HGF ( Figure 7A ). As expected, decoy HGF had increased their size by 2.2-and 6.7-fold, respectively, Met efficiently abrogated the ability of HGF to protect tumor while tumors transduced with decoy Met or NK4 HGF had recells against the toxic effects of radiation. NK4 HGF was also gressed by 4.7-and 2.8-fold, respectively. Thus, HGF protects effective in this system, although to a lesser extent.
tumor cells against radiation; conversely, inhibition of the HGF/ Next, we injected wild-type MDA-MB-435-␤4 cells into CD-1
Met pathway by decoy Met or NK4 HGF synergizes with radionu Ϫ/Ϫ mice, and monitored animals for tumor appearance. Mice therapy in inducing tumor regression. bearing tumors of approximately 100 mm 3 were selected and randomly divided into four groups (n ϭ 6) as described above. Discussion Each group was injected intratumorally with the appropriate lentiviral vector on day 0 and 3, and mice were given a subcuraIn this study, we utilized a lentiviral vector-based gene transfer tive irradiation dose (15 Gy) on day 6. After irradiation, tumor volume was monitored for additional 18 days. Tumors transapproach to investigate the role of HGF in tumor progression, clonal antibodies against HGF showed significant antitumoral activity in experimental animals (Cao et al., 2001 ). However, tumor inhibition was achieved only with a combination of at least three different monoclonal antibodies, each for a distinct epitope of HGF. Since each monoclonal antibody may have its own specificity, pharmacodynamics, biodistribution, side effects, and dose/effect curve, the clinical application of this approach may encounter some complications. As a further concern, neutralizing antibodies against HGF cannot prevent Met activation induced by receptor overexpression, a very common event in human cancer. A different approach achieved downregulation of HGF and/or Met in various experimental systems via U1snRNA/ribozymes (Jiang et al., 2001 ). This technique makes use of a triple combination of a U1snRNA, a hammerhead ribozyme, and an antisense mRNA sequence to downregulate the messenger RNA of a given gene. While this approach may be a valuable tool in target validation studies that employ in vitro engineered cell lines, it cannot have realistic clinical applications as of now, since it is difficult to imagine how to achieve an efficient delivery of the specific ribozyme to every single tumor cell in a patient. Decoy Met, in contrast, is a secreted protein, which makes it possible to achieve a paracrine and/or endocrine effect on all the cellular components of the tumor by gene transfer to only a small fraction of cells. Similar arguments apply to the use of transmembrane, dominant-negative forms of Met (Firon et al., 2000; Furge et al., 2001) .
Recently, small molecule inhibitors against the Met kinase have been developed (Sattler et al., 2003; Christensen et al., 2003; . These compounds prevent ATP from binding to the ATP binding site of Met. This is an interesting pharmacological approach that has achieved successful results for other tyrosine kinases. However, small molecules inhibitors also have their own limitations. First, no ATP analog will ever metabolism, that have to be tested case by case in both preclinical and clinical settings. In the case of the mentioned molecules, no information on these parameters is yet available. Furtherand to explore the therapeutic potential of HGF/Met inhibitors more, none of the quoted studies analyzed metastasis, angioin antineoplastic therapy.
genesis, or the effect of these anti-Met compounds on normal As mentioned in the Introduction, multiple approaches have physiologic functions. been previously attempted to inhibit HGF or Met in experimental Our preclinical data indicate that HGF levels greatly influence systems. Among all the explored routes, the use of NK4 HGF the likelihood of developing metastases. Since HGF is ubiquito displace HGF from Met is certainly the most thoroughly chartous in tissues, and its plasma levels fluctuate in relation to acterized and perhaps the most promising. The in vitro and particular physiological or pathological conditions, our findings preclinical data presented in our study suggest, however, that have important implications in cancer therapy. For example, decoy Met has several biochemical and biological advantages oncological patients who may potentially bear residual tumor over NK4 HGF. First, decoy Met binds to HGF with approxicells-following primary tumor resection and/or chemothermately one log higher affinity than NK4 HGF binds to Met. apy-may be treated with anti-HGF agents to prevent the Second, decoy Met can also inhibit Met activation induced by growth of such cells into manifest metastatic lesions. Alternaligand-independent mechanisms. Third, decoy Met is signifitively, premalignant lesions for which surgical removal may not cantly more effective than NK4 HGF in preventing metastasis, be appropriate could be held in check by HGF antagonists, in order to prevent their malignant conversion. With regard to these and has less pronounced systemic side effects.
In addition, decoy Met may also present some advantages possibilities, our data indeed demonstrate that decoy Met inhibits metastatic spread (1) independently of tumor size, (2) from over other HGF/Met inhibitors. For example, neutralizing mono- versus normal tissues could easily be explained by-and is reasonably a proof of-the hypothesis that tumors are nothing it is noteworthy to observe that hgf or met knockout mice die in utero due to liver failure and placental defects, resulting from
